Expert Review of Anticancer Therapy, Volume 21, Issue 9 (2021)

Browse this journal
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Expert Review of Anticancer Therapy, Volume 21, Issue 9 (2021)

See all volumes and issues
Vol 24, 2024 Vol 23, 2023 Vol 22, 2022 Volume 21, 2021 Vol 20, 2020 Vol 19, 2019 Vol 18, 2018 Vol 17, 2017 Vol 16, 2016 Vol 15, 2015 Vol 14, 2014 Vol 13, 2013 Vol 12, 2012 Vol 11, 2011 Vol 10, 2010 Vol 9, 2009 Vol 8, 2008 Vol 7, 2007 Vol 6, 2006 Vol 5, 2005 Vol 4, 2004 Vol 3, 2003 Vol 2, 2002 Vol 1, 2001
Download citations Download PDFs Download issue

Editorial

Editorial
How can we better distinguish metastatic tumors from primary tumors in the breast?
Tomo Osako
Pages: 913-916
Published online: 28 Jun 2021
First Page PreviewforHow can we better distinguish metastatic tumors from primary tumors in the breast? | Full Text | References | PDF (7.9 MB) | EPUB
  • 1865 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access

Drug profile

Article
Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors
Xiuhua Lu, Shibin Yan, Kelly Ann Koral & Zhongguang Chen
Pages: 917-926
Published online: 29 Jun 2021
AbstractforSurufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors | Full Text | References | PDF (530.5 KB) | EPUB
  • 447 Views
  • 5 CrossRef citations
  • 0Altmetric
Article
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma
Antonio D’Alessio, Antonella Cammarota, Valentina Zanuso, Tiziana Pressiani, Nicola Personeni & Lorenza Rimassa
Pages: 927-939
Published online: 17 Aug 2021
AbstractforAtezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma | Full Text | References | PDF (1.1 MB) | EPUB
  • 616 Views
  • 4 CrossRef citations
  • 0Altmetric
Article
Pembrolizumab in the treatment of refractory primary mediastinal large B-cell lymphoma: safety and efficacy
Vincent Camus, Camille Bigenwald, Vincent Ribrag, Julien Lazarovici, Fabrice Jardin & Clémentine Sarkozy
Pages: 941-956
Published online: 18 Aug 2021
AbstractforPembrolizumab in the treatment of refractory primary mediastinal large B-cell lymphoma: safety and efficacy | Full Text | References | PDF (429.1 KB) | EPUB
  • 338 Views
  • 0 CrossRef citations
  • 0Altmetric

Review

Overview and recent advances in the targeting of medulloblastoma cancer stem cells
Megan Rose Paul & Peter E Zage
Pages: 957-974
Published online: 08 Jun 2021
AbstractforOverview and recent advances in the targeting of medulloblastoma cancer stem cells | Full Text | References | PDF (2.3 MB) | EPUB
  • 595 Views
  • 4 CrossRef citations
  • 0Altmetric
The mechanisms of resistance to second- and third-generation ALK inhibitors and strategies to overcome such resistance
Naoki Haratake, Gouji Toyokawa, Takashi Seto, Tetsuzo Tagawa, Tasuro Okamoto, Koji Yamazaki, Sadanori Takeo & Masaki Mori
Pages: 975-988
Published online: 21 Jun 2021
AbstractforThe mechanisms of resistance to second- and third-generation ALK inhibitors and strategies to overcome such resistance | Full Text | References | PDF (2.1 MB) | EPUB
  • 945 Views
  • 7 CrossRef citations
  • 0Altmetric
The development and clinical use of oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes: dawn of the total oral therapy era
Molly Schiffer, Jennifer Zhao, Aubrey Johnson, Jane Lee, Jan Philipp Bewersdorf & Amer M. Zeidan
Pages: 989-1002
Published online: 28 Apr 2021
AbstractforThe development and clinical use of oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes: dawn of the total oral therapy era | Full Text | References | PDF (1.6 MB) | EPUB
  • 493 Views
  • 2 CrossRef citations
  • 0Altmetric
Immune checkpoint inhibition in classical hodgkin lymphoma
Parmida Sadat Pezeshki, Mahsa Eskian, Michael R Hamblin & Nima Rezaei
Pages: 1003-1016
Published online: 27 Apr 2021
AbstractforImmune checkpoint inhibition in classical hodgkin lymphoma | Full Text | References | PDF (400.7 KB) | EPUB
  • 447 Views
  • 7 CrossRef citations
  • 0Altmetric
New nonchemotherapy treatment options for cutaneous T-cell lymphomas
Suzanne Xu & Francine Foss
Pages: 1017-1028
Published online: 27 Jul 2021
AbstractforNew nonchemotherapy treatment options for cutaneous T-cell lymphomas | Full Text | References | PDF (386.1 KB) | EPUB
  • 345 Views
  • 1 CrossRef citations
  • 0Altmetric
Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence
Matteo Santoni, Roberto Iacovelli, Valentina Colonna, Stephan Klinz, Giorgio Mauri & Marianna Nuti
Pages: 1029-1054
Published online: 27 Aug 2021
AbstractforAntitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence | Full Text | References | PDF (735.8 KB) | EPUB
  • 5074 Views
  • 8 CrossRef citations
  • 0Altmetric
Open Access

Meta-analysis

Article
Impact of anti-cancer therapy on disease severity and mortality in cancer patients with COVID-19: a systematic review and meta-analysis
Zhixian Lin, Jiangfeng Chen & Sunya Han
Pages: 1055-1066
Published online: 18 May 2021
AbstractforImpact of anti-cancer therapy on disease severity and mortality in cancer patients with COVID-19: a systematic review and meta-analysis | Full Text | References | PDF (10.9 MB) | EPUB
  • 234 Views
  • 7 CrossRef citations
  • 0Altmetric

Explore articles

Explore the most recently published articles

Immune-related adverse events associated with mogamulizumab: a comprehensive review of the literature
Genevieve S. Silva et al.
Review Article | Published online: 23 Jul 2024
Bevacizumab-containing treatment for relapsed or refractory Wilms tumor
Sarah Al-Jilaihawi et al.
Review Article | Published online: 23 Jul 2024
UNDERSTANDING the LINK BETWEEN ASPARTAME and CANCER
Morando Soffritti
Report | Published online: 23 Jul 2024
PROTACing the androgen receptor and other emerging therapeutics in prostate cancer
Peter D. Zang et al.
Review Article | Published online: 22 Jul 2024
View all latest articles